Partnership with Dialectic Therapeutics enables launch of clinical trial
FCF is pleased to announce its partnership with Dialectic Therapeutics to supply an experimental drug, DT2216, for a planned clinical trial for fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the manufacturing costs of the drug was crucial to ensure the …